Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01683175
Recruitment Status : Unknown
Verified October 2016 by Tianjin Medical University Cancer Institute and Hospital.
Recruitment status was:  Active, not recruiting
First Posted : September 11, 2012
Last Update Posted : October 20, 2016
Roche Pharma AG
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital

Tracking Information
First Submitted Date  ICMJE August 30, 2012
First Posted Date  ICMJE September 11, 2012
Last Update Posted Date October 20, 2016
Study Start Date  ICMJE August 2012
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 6, 2012)
2-year disease free survival rate (DFSR) [ Time Frame: 2 years ]
2-year disease free survival rate is defined as the estimation percentage of disease free survival patients with study treatment at 2-year.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 6, 2012)
  • disease free survival [ Time Frame: 5 years ]
    Disease free survival is defined as the time from randomization to disease recurrence or death which comes first.
  • overall survival (OS) [ Time Frame: 5 years ]
    Overall survival is defined as the time from randomization to death.
  • Quality of Life [ Time Frame: 5 years ]
    The score of Functional Assessment of Cancer Therapy - Lung (FACT-L) subscale and Lung Cancer Symptom Scale (LCSS)
  • Adverse Event (AE) [ Time Frame: 5 years ]
    frequency of Adverse Event
  • Serious Adverse Event (SAE) [ Time Frame: 5 years ]
    Frequency of Serious Adverse Event (SAE)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation
Official Title  ICMJE A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation
Brief Summary This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Non-small Cell Lung Cancer Stage III
Intervention  ICMJE
  • Drug: Erlotinib
  • Drug: cis-platinum
  • Drug: Vinorelbine
Study Arms  ICMJE
  • Experimental: Arm 1
    Erlotinib 150mg daily oral up to 2 years
    Intervention: Drug: Erlotinib
  • Active Comparator: Arm 2
    NP Chemotherapy for 4 cycles
    • Drug: cis-platinum
    • Drug: Vinorelbine
Publications * Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Wang C. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Unknown status
Actual Enrollment  ICMJE
 (submitted: September 6, 2012)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE October 2020
Estimated Primary Completion Date October 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • IIIA NSCLC patients according to TMN-staging of Lung Staging Standard version 7 2009, confirmed by histopathology or cytology after radical operation, and having EGFR exon 19 deletion mutation or exon 21 L858R single base substitution;
  • Accept study adjuvant therapy within 6 weeks post radical operation;
  • ECOP PS 0-1; Life expectancy ≥12 weeks;
  • Hematology: absolute neutrophil count (ANC) ≥1.5×10^9/L; platelet count ≥100×10^9/L; hemoglobin concentration ≥ 9.0 g/dL (permit to maintain hematologic criteria by blood transfusion);
  • Liver Function: TBil ≤1.5xULN; ALT and AST ≤2.5xULN;
  • Renal Function: Cr ≤1.25xULN, and Ccr ≥60ml/min;
  • Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days before study treatment;
  • Signed inform consent form by patient or his/her legal representative;
  • Comply with study protocol and procedure, and be able to take oral medication; Aged ≥18 years and ≦75 years;
  • Eligible patients of reproductive potential (both sexes) must agree to use a reliable method of birth control before enrollment, during the study period and for at least 30 days after their last dose of study therapy;

Exclusion Criteria:

  • Having treated by Her-Target therapy, i.e. erlotinib, gefitinib, cetuximab, trastuzumab;
  • Having treated by any systemic anti-tumor therapy of NSCLC, including cytotoxic therapy, target medication treatment (i.e. monoclonal antibody), investigational therapy;
  • Having local radiotherapy of NSCLC; Upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer;
  • The findings in radical operation are lymph nodes with extracapsular invasion, or fusion, or all of dissection lymph nodes positive by pathology;
  • Diagnosed other malignant tumor besides NSCLC within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival,cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor);
  • Confirmed recurrent cancer by Clinical objective evidence (pathology or radiography images) before the study adjuvant therapy;
  • Known hypersensitivity to platinum, Vinorelbine, EGFR-TKI agents or relevant components in the formulation;
  • Uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection;
  • Active interstitial lung disease (ILD) by any clinical evidence; patients with any co-morbidities, or motalic disorders, or any abnormal findings in physical examination or laboratory tests are suspected to have contraindication of study therapy or high risk of study treatment complications;
  • Any unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, angina starting in latest 3 months, Congestive heart failure (NYHA ≥ II), myocardial infarction within 6 months prior enrollment, under medication treatment of severe arrhythmia, liver, renal or metabolic disease;
  • know HIV infection Pregnant or breastfeeding women;
  • ECOG PS ≥2;
  • Mixed with small cell lung cancer;
  • Other conditions investigators evaluate that patient is not eligible to this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01683175
Other Study ID Numbers  ICMJE ML28280
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Tianjin Medical University Cancer Institute and Hospital
Study Sponsor  ICMJE Tianjin Medical University Cancer Institute and Hospital
Collaborators  ICMJE Roche Pharma AG
Investigators  ICMJE
Principal Investigator: Changli Wang Tianjin Medical University Cancer Institute and Hospital
PRS Account Tianjin Medical University Cancer Institute and Hospital
Verification Date October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP